Bio pharmaceutical Business Unit

The bio-pharmaceuticals business unit has become a leader in the field with sustained growth,
momentum, and stability through continuous research and development.


Motivated by the urgent need for medication for patients, the bio-pharmaceuticals division remains dedicated to research and development.

In 2014, the unit successfully commercialized Neuronata-R inj, a stem cell therapy for the rare disease Amyotrophic Lateral Sclerosis (ALS), making it the fifth stem cell therapy approved for use globally.

Alongside ALS treatment, the division has pipelines for various diseases such as lupus, Neuromyelitis Optica (NMO), and multiple system atrophy (MSA). Leveraging the success of the ALS stem cell therapy, the unit plans to concentrate on developing treatments for rare and incurable neurological and autoimmune diseases to dominate new market.

With innovative research and technology, the unit aims to overcome national, racial, and income boundaries by providing new treatment alternatives for rare and currently incurable diseases where no treatment exists, and by developing stem cell therapies that influence the world stage with a competitive edge.

Thank you

From all employees CORESTEMCHEMON Inc.